Share on StockTwits

Biota Pharmaceuticals (NASDAQ:BOTA) EVP Joseph M. Patti bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, June 27th. The shares were purchased at an average cost of $2.81 per share, with a total value of $14,050.00. Following the purchase, the executive vice president now directly owns 67,241 shares of the company’s stock, valued at approximately $188,947. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Separately, analysts at TheStreet downgraded shares of Biota Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 30th.

Biota Pharmaceuticals (NASDAQ:BOTA) opened at 2.95 on Wednesday. Biota Pharmaceuticals has a 52 week low of $2.35 and a 52 week high of $7.07. The stock’s 50-day moving average is $2.87 and its 200-day moving average is $4.63. The company’s market cap is $103.5 million.

Biota Pharmaceuticals (NASDAQ:BOTA) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.37. On average, analysts predict that Biota Pharmaceuticals will post $-0.22 earnings per share for the current fiscal year.

Biota Pharmaceuticals, Inc, formerly Nabi Biopharmaceuticals, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.